Cargando…

Identification of aurora kinase A as an unfavorable prognostic factor and potential treatment target for metastatic gastrointestinal stromal tumors

Although imatinib mesylate (IM) has revolutionized the management of gastrointestinal stromal tumors (GISTs), drug resistance remains a challenge. Previous studies have shown that the expression of aurora kinase A (AURKA) predicts recurrence in patients with primary, surgically resected GISTs. The c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yeh, Chun-Nan, Yen, Chueh-Chuan, Chen, Yen-Yang, Cheng, Chi-Tung, Huang, Shih-Chiang, Chang, Ting-Wei, Yao, Fang-Yi, Lin, Yung-Chan, Wen, Yao-Shan, Chiang, Kun-Chun, Chen, Jen-Shi, Yeh, Ta-Sen, Tzeng, Cheng-Hwai, Chao, Ta-Chung, Fletcher, Jonathan A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2014
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4147307/ https://www.ncbi.nlm.nih.gov/pubmed/24901229

Ejemplares similares

Role of PLK1 signaling pathway genes in gastrointestinal stromal tumors
por: Chen, Jen-Shi, et al.
Publicado: (2018)

Fractioned Dose Regimen of Sunitinib for Patients with Gastrointestinal Stromal Tumor: A Pharmacokinetic and Treatment Efficacy Study()
por: Chen, Yen-Yang, et al.
Publicado: (2014)

Feasibility and Timing of Cytoreduction Surgery in Advanced (Metastatic or Recurrent) Gastrointestinal Stromal Tumors During the Era of Imatinib
por: Chang, Shih-Chun, et al.
Publicado: (2016)

Regorafenib treatment outcome for Taiwanese patients with metastatic gastrointestinal stromal tumors after failure of imatinib and sunitinib: A prospective, non-randomized, single-center study
por: Hu, Chia-Hsiang, et al.
Publicado: (2020)

Prospective Evaluation of Neoadjuvant Imatinib Use in Locally Advanced Gastrointestinal Stromal Tumors: Emphasis on the Optimal Duration of Neoadjuvant Imatinib Use, Safety, and Oncological Outcome
por: Wang, Shang-Yu, et al.
Publicado: (2019)

Compassionate Use of Ripretinib for Patients With Metastatic Gastrointestinal Stromal Tumors: Taiwan and Hong Kong Experience
por: Lin, Li-Ching, et al.
Publicado: (2022)

Corrigendum: Compassionate use of ripretinib for patients with metastatic gastrointestinal stromal tumors: Taiwan and Hong Kong experience
por: Lin, Li-Ching, et al.
Publicado: (2022)

A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17
por: Yeh, Chun-Nan, et al.
Publicado: (2017)

Autophagy is involved in endogenous and NVP-AUY922-induced KIT degradation in gastrointestinal stromal tumors
por: Hsueh, Yuan-Shuo, et al.
Publicado: (2013)

Targeted ultra-deep sequencing unveils a lack of driver-gene mutations linking non-hereditary gastrointestinal stromal tumors and highly prevalent second primary malignancies: random or nonrandom, that is the question
por: Lai, Bo-Ru, et al.
Publicado: (2016)

Evaluation of prognostic factors and the role of chemotherapy in unfavorable carcinoma of unknown primary site: a 10-year cohort study
por: Chen, Kuo-Wei, et al.
Publicado: (2012)

Non‐small cell lung cancer with gastric metastasis and repeated gastrointestinal bleeding: A rare case report and literature review
por: Shih‐Chun, Chang, et al.
Publicado: (2021)

Peritumoral SPARC expression and patient outcome with resectable intrahepatic cholangiocarcinoma
por: Cheng, Chi-Tung, et al.
Publicado: (2015)

Cytoreductive Surgery may be beneficial for highly selected patients with Metastatic Gastrointestinal Stromal Tumors receiving Regorafenib facing Local Progression: A Case Controlled Study
por: Yeh, Chun-Nan, et al.
Publicado: (2021)

Prediction of Gastric Gastrointestinal Stromal Tumors before Operation: A Retrospective Analysis of Gastric Subepithelial Tumors
por: Lin, Yu-Ning, et al.
Publicado: (2022)

Transcriptomic reappraisal identifies MGLL overexpression as an unfavorable prognosticator in primary gastrointestinal stromal tumors
por: Li, Chien-Feng, et al.
Publicado: (2016)

Identification of SPHK1 as a therapeutic target and marker of poor prognosis in cholangiocarcinoma
por: Chen, Ming-Huang, et al.
Publicado: (2015)

Clinical effect of a positive surgical margin after hepatectomy on survival of patients with intrahepatic cholangiocarcinoma
por: Yeh, Chun-Nan, et al.
Publicado: (2014)

Aspartate and Acetate Fuel Gastrointestinal Stromal Tumors Beyond the Warburg Effect
por: Lai, Ying-Chieh, et al.
Publicado: (2022)

Interferon α-inducible protein 27 is an oncogene and highly expressed in cholangiocarcinoma patients with poor survival
por: Chiang, Kun-Chun, et al.
Publicado: (2019)

Aurora kinase A (AURKA) promotes the progression and imatinib resistance of advanced gastrointestinal stromal tumors
por: Cheng, Xiaobin, et al.
Publicado: (2021)

Selecting Tyrosine Kinase Inhibitors for Gastrointestinal Stromal Tumor with Secondary KIT Activation-Loop Domain Mutations
por: Hsueh, Yuan-Shuo, et al.
Publicado: (2013)

HO-1 is a favorable prognostic factor for HBV-HCC patients who underwent hepatectomy
por: Yeh, Chun-Nan, et al.
Publicado: (2018)

Lipocalin 2 (LCN2) is a promising target for cholangiocarcinoma treatment and bile LCN2 level is a potential cholangiocarcinoma diagnostic marker
por: Chiang, Kun-Chun, et al.
Publicado: (2016)

Imatinib dose escalation versus sunitinib as a second-line treatment against advanced gastrointestinal stromal tumors: A nationwide population-based cohort study
por: Hsu, Jun-Te, et al.
Publicado: (2017)

MTOR inhibition enhances NVP-AUY922-induced autophagy-mediated KIT degradation and cytotoxicity in imatinib-resistant gastrointestinal stromal tumors
por: Hsueh, Yuan-Shuo, et al.
Publicado: (2014)

Complex IV subunit 1 defect predicts postoperative survival in hepatocellular carcinoma
por: LE, PUO-HSIEN, et al.
Publicado: (2014)

Discovery and Synthesis of a Pyrimidine-Based Aurora Kinase Inhibitor to Reduce Levels of MYC Oncoproteins
por: Chi, Ya-Hui, et al.
Publicado: (2021)

Three-year mortality in cryptococcal meningitis: Hyperglycemia predict unfavorable outcome
por: Tsai, Sheng-Ta, et al.
Publicado: (2021)

N3 Subclassification Incorporated into the Final Pathologic Staging of Gastric Cancer: A Modified System Based on Current AJCC Staging
por: Yeh, Chun-Nan, et al.
Publicado: (2015)

Impact of Aurora Kinase A Polymorphism and Epithelial Growth Factor Receptor Mutations on the Clinicopathological Characteristics of Lung Adenocarcinoma
por: Yang, Po-Jen, et al.
Publicado: (2020)

Prognostic Value of the Preoperative Neutrophil to Lymphocyte Ratio in Resectable Gastric Cancer
por: Hsu, Jun-Te, et al.
Publicado: (2015)

MART-10 represses cholangiocarcinoma cell growth and high vitamin D receptor expression indicates better prognosis for cholangiocarcinoma
por: Chiang, Kun-Chun, et al.
Publicado: (2017)

Chemopreventive and chemotherapeutic effects of dietary supplementation of vitamin D on cholangiocarcinoma in a Chemical-Induced animal model
por: Chiang, Kun-Chun, et al.
Publicado: (2014)

Predictors of unfavorable outcome at 90 days in basilar artery occlusion patients
por: Chiu, Yu-Chen, et al.
Publicado: (2022)

MART-10, a New Generation of Vitamin D Analog, Is More Potent than 1α,25-Dihydroxyvitamin D(3) in Inhibiting Cell Proliferation and Inducing Apoptosis in ER+ MCF-7 Breast Cancer Cells
por: Chiang, Kun-Chun, et al.
Publicado: (2012)

Systemic Therapy for Gastrointestinal Stromal Tumor: Current Standards and Emerging Challenges
por: Huang, Wen-Kuan, et al.
Publicado: (2022)

Effect of Relative Humidity on Adsorption Breakthrough of CO(2) on Activated Carbon Fibers
por: Chiang, Yu-Chun, et al.
Publicado: (2017)

The rural - urban divide in ambulatory care of gastrointestinal diseases in Taiwan
por: Lin, Yi-Hsuan, et al.
Publicado: (2013)

Mucin 4 Confers Gemcitabine Resistance and an Unfavorable Prognosis in Patients with Cholangiocarcinoma via AKT Activation
por: Pan, Yi-Ru, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ptmd56qltpjo68dj5jbqaoqbj3